MichaelA.CaligiuriMD

Immediate Past President, Deana and Steve Campbell Physician-in-Chief Distinguished Chair. Currently Professor, City of Hope National Medical Center

Join to view full profile

Dr. Caligiuri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Caligiuri's full profile

Already have an account?

Office
1500 E. Duarte Road
Duarte, CA 91010
Phone+1 626-218-4325

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1989
Brigham and Women's HospitalResidency, Internal Medicine, 1983 - 1986
Stanford University School of MedicineClass of 1983
Stanford University School of MedicineMA, Physiology, 1980 - 1982
State University of New York at BuffaloBA, Humanities and Health Science, Summa Cum Laude, 1974 - 1978

Certifications & Licensure

CA State Medical License 2019 - 2025
OH State Medical License 1997 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Basic Science Mentor Award American Society of Hematology, 2022
Elected Fellow of the AACR Academy The American Association for Cancer Research, 2018
Elected Member US National Academy of Medicine, 2018
Elected President American Association for Cancer Research (AACR), 2017-2018
Elected President Society for Natural Immunity, 2015-2017
Elected President Association for American Cancer Institutes (AACI), 2009-2011
Elected Member American Association of Physicians (AAP), 2004
Elected Fellow American Association for the Advancement of Science (AAAS), 2003
Elected Fellow (FACP) American College of Physicians, 1998
Elected Member The American Society for Clinical Investigation, 1998
Join now to see all

Clinical Trials

Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia Start of enrollment: 1999 Feb 01
Completed
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting

Publications & Presentations

PubMed

Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors.
Zhenlong Li, Rui Ma, Hejun Tang, Michael A Caligiuri, Jianhua Yu
STAR Protocols. 2024-09-20
Enhanced treatment of breast cancer brain metastases with oncolytic virus expressing anti-CD47 antibody and temozolomide.
Jing Wang, Lei Tian, Tasha Barr, Lewei Jin, Yuqing Chen
Molecular Therapy. Oncology. 2024-09-19
8 citations
Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.
Zahir Shah, Lei Tian, Zhixin Li, Lewei Jin, Jianying Zhang
Cell Stem Cell. 2024-06-06

Journal Articles

Human AML Activates the AHR Pathway to Impair NK Cell Development and Function
Luxi Chen, Michael Zhang, Monica Williams, Jennifer N Saultz, Steven D Scoville, Aharon G Freud, Don M Benson, Michael A Caligiuri, Blood

Abstracts/Posters

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia
Michael A. Caligiuri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
Andrew T. Leitner, M.D., Appointed Chair of City of Hope Department of Supportive Care MedicineApril 17th, 2023
City of Hope Scientists Reveal How XBP1s Interacts with IL-15 to Enhance the Survival of Natural Killer CellsMarch 13th, 2023
Join now to see all

Grant Support

Cancer Center Support GrantNational Cancer Institute2011–2012
IL-15 Characterization Through Experimental ImmunologyNational Cancer Institute2010–2012
Functional Characterization Of MLL Gene FusionsNational Cancer Institute2002–2012
Pre-Clinical And Clinical Investigation Of Mll-Ptd Acute Myeloid LeukemiaNational Cancer Institute2009–2011
Innate Immunity: Elucidation And Modulation For Cancer TherapyNational Cancer Institute2007–2011
Elucidation &Modulation Of Natural Killer Cell Signaling: Application In CancerNational Cancer Institute2007–2011
Oncology Training GrantNational Cancer Institute1998–2011
The Ohio State University Comprehensive Cancer CenterNational Cancer Institute2005–2010
Cancer And Leukemia Group B - Leukemia Correlative SciencesNational Cancer Institute2009
Senior LeadershipNational Cancer Institute2005–2009
Protocol Specific Research SupportNational Cancer Institute2005–2009
Program Planning &EvaluationNational Cancer Institute2005–2009
IL-15 Characterization Through Experimental ImmunologyNational Cancer Institute2005–2009
Developmental FundsNational Cancer Institute2005–2009
Cancer And Leukemia Group B-Leukemia Correlative ScienceNational Cancer Institute2003–2008
The Ohio State University Comprehensive Cancer Center-SupplementNational Cancer Institute2007
Administration, Budgeting, And OperationsNational Cancer Institute2007
Innate Immunity: Elucidation/Modulation - Cancer TherapyNational Cancer Institute2002–2006
A Phase I Study Of Low-Dose Subcutaneous Interleukin 2National Center For Research Resources2004
Comprehensive Cancer CenterNational Cancer Institute2003–2004
IL 15--Characterization Through Experimental ImmunologyNational Cancer Institute2000–2004
Onocology Training GrantNational Cancer Institute1999–2003
Immune Regulation By Natural Killer Cell SubsetsNational Cancer Institute2002
Novel Immune Modulation In AIDS And AIDS MalignancyNational Cancer Institute2001–2002
Therapy For AIDS Central Nervous System LymphomaNational Cancer Institute1999–2002
7th Annual Meeting Of The Society Of Natural ImmunityNational Cancer Institute2001
Phase I Study Of G3139 (Nsc 683428) In Combination With Salvage ChemotherapyNational Center For Research Resources2000
Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute1999–2000
Natural Killer Cell Development And Function In HIV1National Cancer Institute1998–1999
Il-15--Characterization Through Experimental ImmunologyNational Cancer Institute1997–1999
Biological Response Modifiers In AIDS MalignanciesNational Cancer Institute1997–1998
Il-15--Characterization Through Experimental ImmunologyNational Cancer Institute1996
Biological Response Modifiers In AIDS MalignanciesNational Cancer Institute1995–1996
Cytokines And Lymphomagenesis Of AIDSNational Cancer Institute1994–1996
Thymic Derived NK CellsNational Cancer Institute1994
Characterization Of Thymic Derived NK CellsNational Cancer Institute1990–1993